Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?

Conditions

• Multiple Sclerosis
• Multiple Sclerosis (MS) - Relapsing-remitting
• RRMS

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Not accepted

Interventions

• Early Cerebro-spinal MRI — OTHER
  A standardized MRI of the brain and spinal cord with gadolinium injection. Performed very early during an acute neurological exacerbation, specifically between Day 0 and Day 6 (J0 to J6). To detect the presence or absence of gadolinium-enhancing lesions, which is the study's primary endpoint. Includes Susceptibility Weighted Imaging (SWI) to look for paramagnetic rim lesions and post-gadolinium FLAIR sequences to detect leptomeningeal enhancement.
• Biomarker Assessment — DIAGNOSTIC_TEST
  Routine blood and urine tests, including CRP, blood count, and urinalysis (leukocytes, nitrites) to rule out infections that could cause a pseudo-relapse. Ancillary Study Biomarkers: For consenting patients, blood samples are collected to measure specific molecular markers: NfL (Neurofilaments): A marker of axonal damage. GFAP (Glial Fibrillary Acidic Protein): A marker of astrocytic activation. cfDNA (Cell-free DNA): Used to assess cellular stress or death
• Clinical and Neuropsychological Evaluations — DIAGNOSTIC_TEST
  Standardized Scales: * EDSS (Expanded Disability Status Scale): Used to measure the degree of neurological disability at inclusion and at the 6-month follow-up. * SDMT (Symbol Digit Modalities Test) and CSCT (Computerized Speed Cognitive Test): Used to assess cognitive processing speed. Functional Disorder Screening: A specific clinical examination is conducted to identify positive signs of Functional Neurological Disorders (FND/TNF), which may mimic a relapse.

Study Details

The MYTH-MS study is a multicenter prospective study investigating the occurrence of clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) in the absence of radiological activity on MRI. While MS relapses are typically associated with gadolinium-enhancing lesions on MRI, some patients present with acute neurological symptoms without radiological correlates, referred to as acute clinical events with stable MRI (ACES). The frequency, mechanisms, and clinical relevance of these events remain unclear due to limitations in previous studies. The primary objective is to determine the proportion of RRMS patients experiencing a relapse without gadolinium-enhancing lesions on early brain and spinal MRI. Secondary objectives include identifying clinical, radiological, biological, and psychological predictors, assessing neurologists' diagnostic accuracy, and evaluating clinical outcomes such as disability, cognition, and quality of life over a 6-month follow-up. A total of 136 patients with recent neurological exacerbations will be included. Each participant will undergo clinical assessment, cognitive and psychological evaluation, and early MRI, with follow-up at 6 months. An ancillary study will explore blood biomarkers (NfL, GFAP, and circulating DNA) to help differentiate true inflammatory relapses from ACES. This study aims to improve the understanding and diagnosis of MS exacerbations and to optimize patient management by reducing misdiagnosis and unnecessary treatments.

Key Dates

First listed

Apr 22, 2026

Start date

Sep 1, 2026

Status verified

Apr 2026

Primary completion

Sep 7, 2029

Completion

May 1, 2030

Study Design

Enrollment

136 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Arms

• Experimental: RRMS Patients with Acute Neurological Exacerbations

Primary Outcome Measure

Proportion of RRMS Patients with Absence or Presence of Gadolinium-Enhancing Lesion(s) on Brain and Spinal Cord MRI [ Time Frame: performed between Day 0 and Day 6 ]

Central Contacts

• Kévin BIGAUT, MCU-PH
  +33 (0)3 88 12 85 68
  [email protected]

Find similar trials

Related Studies

• Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
  Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
• Serum Auto-Antibodies in Neurological Diseases
  Enrolling By Invitation · University of California, Davis · Sacramento, California
• Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• NARCOMS Registry: A Multiple Sclerosis Registry
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas